BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.
BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.
Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company.
BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.
BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.
Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company.
BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.
Location: Netherlands, North Holland, Naarden
Employees: 11-50
Founded date: 2006
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 24
| Date | Name | Website | Total Raised | Location |
| 25.02.2022 | Cision | prnewswire.com | - | - |
| 25.02.2022 | VectorY | vectorytx.com | $178.32M | Netherland... |
| 25.02.2022 | Complement... | complementtx.com | $84.66M | United Kin... |
| 25.02.2022 | Dunad | dunad.co.uk | - | - |
| 18.08.2021 | NewAmsterd... | newamsterdampharma.com | $377.6M | - |
| 18.08.2021 | Fibrocor | fibrocortherapeutics.com | - | - |
| 18.08.2021 | Mironid® L... | mironid.com | $6.31M | United Kin... |
| 18.08.2021 | NewAmsterd... | citryll.com | $37.72M | - |
| 03.08.2021 | Dezima Pha... | investors.amgen.com | - | United Sta... |
| 03.08.2021 | Progentix ... | progentix.com | - | - |
Show more
Mentions in press and media 24
| Date | Title | Description |
| 26.07.2024 | Brenig Therapeutics: Neurology-Focused Drug Development Company Secures $65 Million In Series A | Brenig Therapeutics – a neurology-focused drug development company utilizing an AI/ML-based discovery platform – announced the closing of a $65 million Series A funding. The funding was led by New Enterprise Associates (NEA) with support fr... |
| 12.03.2024 | Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients | Major milestone reached in bringing new treatment options to patients and their families Leiden, The Netherlands, March 12, 2024 – Azafaros B.V. today announced the completion of its 12-week Phase 2 clinical study, RAINBOW (Phase 2 RAINBOW ... |
| 02.10.2023 | 'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023 | While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had problems bringing in money. In fact, both Forbion and BioGeneration Ventures announced their largest ... |
| 19.07.2023 | Dutch biotech River BioMedics raises €2M to discover, develop novel cardiac drugs | Read this article in: Enschede-based River BioMedics, a Dutch biotech company focused on cardiac drug discovery using 3D human cardiac models, announced that it has secured €2M in a seed round of funding. The Dutch startup aims to progress ... |
| 13.07.2023 | BioGeneration Ventures Closes BGV Fund V, at €150M | BioGeneration Ventures (BGV), a Naarden, The Netherlands-based early-stage VC in European biopharma, closed BGV V, at €150m. LPs included US institutional investors and corporate investors including Eli Lilly and Company, Novo Holdings and ... |
| 11.05.2023 | Il mercato del Venture Capital ad aprile 2023 | Come è andato il mercato del Venture Capital ad aprile 2023? Facciamo insieme una carrellata delle startup, delle scaleup e dei round più interessanti. Purtroppo, i dati del primo trimestre 2023 confermano i trend negativi in Europa per gli... |
| 18.11.2022 | FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant | November 17, 2022 |
| 26.09.2022 | Amsterdam-based Phosphoenix bags funds to help blind people regain functional vision: Know more | Amsterdam-based Phosphoenix, a company that is working to help blind people regain functional vision even after extensive damage to the eye or optic nerve, announced on Thursday, September 22, that it raised an undisclosed amount of funding... |
| 01.10.2021 | BGV closes $110M fund | Benhamou Global Ventures has raised $110 million for its fourth flagship fund. The Palo Alto-based VC firm invests in cloud-native, AI- and automation-driven companies; its portfolio includes Totango, Flytrex and Virtana. View fund |
| 30.09.2021 | BGV closes fourth fund with $110M aimed at immigrant enterprise AI, cross-border startups | Silicon Valley-based venture capital (VC) firm Benhamou Global Ventures, known as BGV, closed its fourth fund with $110 million to support global enterprise companies. The new fund is 60% larger than its third fund and will be invested simi... |
Show more